首页 > 最新文献

Advances in biomarker sciences and technology最新文献

英文 中文
Leveraging lean 4.0 technologies in healthcare: An exploration of its applications 在医疗保健领域利用精益 4.0 技术:应用探索
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.08.001
Mohd Javaid , Abid Haleem , Ravi Pratap Singh , Sumit Gupta

Lean 4.0, a fusion of lean manufacturing and digital technologies, is a powerful tool for implementing Industry 4.0. Its widespread use across sectors is driven by its ability to eliminate waste, reduce errors, boost revenue, and enhance customer care and efficiency. In the healthcare sector, this fourth lean revolution is particularly beneficial, as it helps to curb wastage and enhance efficiency, leading to more effective outcomes. Lean 4.0, a globally recognized best practice for industrial organisations, has proven its worth in enhancing performance and competitiveness. Its success has led to its adoption not only in manufacturing but also in non-manufacturing sectors such as Healthcare, finance, telecommunications, construction, and logistics. Its ease of use and effectiveness make it a superior alternative to traditional medical waste management techniques. Relevant papers on Lean 4.0 for Healthcare in the current literature are identified and studied to evaluate the impact of Lean 4.0 principles in Healthcare. This review-based research studies Lean 4.0 technologies and their needs in Healthcare. It discusses sustainable support for the healthcare sphere through Lean 4.0. Paper briefs several modalities of Lean 4.0 for the healthcare domain. Finally, the paper identifies and discusses the significant applications of Lean 4.0 in Healthcare. Lean 4.0 is essential to lowering errors that lead to medical mistakes since this business deals with life-or-death situations. Healthcare institutions need to reduce their overall waste reduction. With Lean 4.0, staff members working in quality management, clinical operations, consulting, and patient experience can progress into leadership roles in the healthcare sector. Lean 4.0 technologies can reduce waste production, including employing reusable medical equipment or cutting down on packaging waste. The possible difficulty of integrating digital technologies with healthcare systems and practices is Lean 4.0's limitations for the healthcare industry. Healthcare institutions can use refillable syringes and other disposable items to reduce waste rather than disposable plastic syringes. In future, healthcare institutions may save costs and lessen their environmental effect by minimising trash by using lean 4.0 technologies.

精益 4.0 是精益生产和数字技术的融合,是实施工业 4.0 的有力工具。精益 4.0 能够消除浪费、减少失误、增加收入、提高客户服务水平和效率,因而在各行各业得到广泛应用。在医疗保健行业,第四次精益革命尤其有益,因为它有助于遏制浪费和提高效率,从而带来更有效的成果。精益 4.0 是全球公认的工业组织最佳实践,已证明其在提高绩效和竞争力方面的价值。精益 4.0 的成功使其不仅被制造业采用,还被医疗保健、金融、电信、建筑和物流等非制造业部门采用。它的易用性和有效性使其成为传统医疗废物管理技术的优越替代品。我们在现有文献中找出并研究了有关医疗保健领域精益 4.0 的相关论文,以评估精益 4.0 原则在医疗保健领域的影响。这项基于综述的研究探讨了精益 4.0 技术及其在医疗保健领域的需求。论文讨论了通过精益 4.0 为医疗保健领域提供可持续支持的问题。论文简要介绍了医疗保健领域精益 4.0 的几种模式。最后,本文确定并讨论了精益 4.0 在医疗保健领域的重要应用。精益 4.0 对于降低导致医疗失误的错误至关重要,因为医疗行业涉及生死存亡。医疗机构需要减少整体浪费。通过精益 4.0,从事质量管理、临床运营、咨询和患者体验工作的员工可以晋升为医疗保健行业的领导者。精益 4.0 技术可以减少废物的产生,包括采用可重复使用的医疗设备或减少包装废物。将数字技术与医疗系统和实践相结合可能存在的困难是精益 4.0 在医疗行业的局限性。医疗机构可以使用可重复使用的注射器和其他一次性物品,而不是一次性塑料注射器,以减少浪费。未来,医疗机构可通过使用精益 4.0 技术减少垃圾,从而节约成本并减轻对环境的影响。
{"title":"Leveraging lean 4.0 technologies in healthcare: An exploration of its applications","authors":"Mohd Javaid ,&nbsp;Abid Haleem ,&nbsp;Ravi Pratap Singh ,&nbsp;Sumit Gupta","doi":"10.1016/j.abst.2024.08.001","DOIUrl":"10.1016/j.abst.2024.08.001","url":null,"abstract":"<div><p>Lean 4.0, a fusion of lean manufacturing and digital technologies, is a powerful tool for implementing Industry 4.0. Its widespread use across sectors is driven by its ability to eliminate waste, reduce errors, boost revenue, and enhance customer care and efficiency. In the healthcare sector, this fourth lean revolution is particularly beneficial, as it helps to curb wastage and enhance efficiency, leading to more effective outcomes. Lean 4.0, a globally recognized best practice for industrial organisations, has proven its worth in enhancing performance and competitiveness. Its success has led to its adoption not only in manufacturing but also in non-manufacturing sectors such as Healthcare, finance, telecommunications, construction, and logistics. Its ease of use and effectiveness make it a superior alternative to traditional medical waste management techniques. Relevant papers on Lean 4.0 for Healthcare in the current literature are identified and studied to evaluate the impact of Lean 4.0 principles in Healthcare. This review-based research studies Lean 4.0 technologies and their needs in Healthcare. It discusses sustainable support for the healthcare sphere through Lean 4.0. Paper briefs several modalities of Lean 4.0 for the healthcare domain. Finally, the paper identifies and discusses the significant applications of Lean 4.0 in Healthcare. Lean 4.0 is essential to lowering errors that lead to medical mistakes since this business deals with life-or-death situations. Healthcare institutions need to reduce their overall waste reduction. With Lean 4.0, staff members working in quality management, clinical operations, consulting, and patient experience can progress into leadership roles in the healthcare sector. Lean 4.0 technologies can reduce waste production, including employing reusable medical equipment or cutting down on packaging waste. The possible difficulty of integrating digital technologies with healthcare systems and practices is Lean 4.0's limitations for the healthcare industry. Healthcare institutions can use refillable syringes and other disposable items to reduce waste rather than disposable plastic syringes. In future, healthcare institutions may save costs and lessen their environmental effect by minimising trash by using lean 4.0 technologies.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 138-151"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000127/pdfft?md5=cb3207d4120894b22c39ecd012cbb1b4&pid=1-s2.0-S2543106424000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141963708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanomedicine in cancer therapy: Advancing precision treatments 癌症治疗中的纳米医学:推进精准治疗
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.06.003
Abdullahi Tunde Aborode , Ayomide Samson Oluwajoba , Aminat Modupe Ibrahim , Shahzaib Ahmad , Aashna Mehta , Osasere Jude-Kelly Osayawe , Damilola Oyebode , Oluwaseun Akinsola , Abraham Osinuga , Isreal Ayobami Onifade , Ibrahim O. Adelakun , Ridwan Olamilekan Adesola , Taiwo Bakare Abidola , Adedeji Daniel Ogunyemi , Oluwaseun Adeolu Ogundijo , Olamilekan Gabriel Banwo , Chibuzo H. Obiechefu

The progress made in the field of nanotechnology has resulted in the development of nanomedicine agents, which have demonstrated their efficacy as a promising clinical tool in the fight against different types of cancers. Furthermore, Nanomedicine products possess the potential to achieve intricate targeting strategies and multifunctionality. Currently, nanoparticles possess diverse applications across various scientific disciplines and serve as a crucial component in contemporary medical practices. The specimens have undergone analysis for diverse clinical purposes, including serving as drug carriers, delivering tumor genes, and functioning as contrast compounds in imaging. Diverse nanomaterials derived from organic, inorganic, lipid, or glycan compounds, in addition to synthetic polymers, have been employed to advance and enhance novel cancer therapeutics. The present review centers on the utilization of nanoparticles in clinical settings for the purposes of cancer diagnosis and treatment, with a particular emphasis on their function as drug carriers and targeted therapy agents.

纳米技术领域取得的进展导致了纳米医药制剂的开发,这些制剂已经证明了其作为抗击不同类型癌症的临床工具的有效性。此外,纳米药物产品还具有实现复杂靶向策略和多功能性的潜力。目前,纳米粒子在各个科学领域都有不同的应用,是当代医疗实践中的重要组成部分。这些标本已被用于不同的临床目的,包括作为药物载体、传递肿瘤基因和在成像中作为造影剂。除合成聚合物外,从有机、无机、脂质或糖类化合物中提取的各种纳米材料已被用于推进和加强新型癌症疗法。本综述的重点是纳米粒子在癌症诊断和治疗中的临床应用,特别强调其作为药物载体和靶向治疗药物的功能。
{"title":"Nanomedicine in cancer therapy: Advancing precision treatments","authors":"Abdullahi Tunde Aborode ,&nbsp;Ayomide Samson Oluwajoba ,&nbsp;Aminat Modupe Ibrahim ,&nbsp;Shahzaib Ahmad ,&nbsp;Aashna Mehta ,&nbsp;Osasere Jude-Kelly Osayawe ,&nbsp;Damilola Oyebode ,&nbsp;Oluwaseun Akinsola ,&nbsp;Abraham Osinuga ,&nbsp;Isreal Ayobami Onifade ,&nbsp;Ibrahim O. Adelakun ,&nbsp;Ridwan Olamilekan Adesola ,&nbsp;Taiwo Bakare Abidola ,&nbsp;Adedeji Daniel Ogunyemi ,&nbsp;Oluwaseun Adeolu Ogundijo ,&nbsp;Olamilekan Gabriel Banwo ,&nbsp;Chibuzo H. Obiechefu","doi":"10.1016/j.abst.2024.06.003","DOIUrl":"https://doi.org/10.1016/j.abst.2024.06.003","url":null,"abstract":"<div><p>The progress made in the field of nanotechnology has resulted in the development of nanomedicine agents, which have demonstrated their efficacy as a promising clinical tool in the fight against different types of cancers. Furthermore, Nanomedicine products possess the potential to achieve intricate targeting strategies and multifunctionality. Currently, nanoparticles possess diverse applications across various scientific disciplines and serve as a crucial component in contemporary medical practices. The specimens have undergone analysis for diverse clinical purposes, including serving as drug carriers, delivering tumor genes, and functioning as contrast compounds in imaging. Diverse nanomaterials derived from organic, inorganic, lipid, or glycan compounds, in addition to synthetic polymers, have been employed to advance and enhance novel cancer therapeutics. The present review centers on the utilization of nanoparticles in clinical settings for the purposes of cancer diagnosis and treatment, with a particular emphasis on their function as drug carriers and targeted therapy agents.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 105-119"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000103/pdfft?md5=047f325cd4a8218462e22114585218a1&pid=1-s2.0-S2543106424000103-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141484836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the role of miR-361-3p in gastric cancer therapeutics and tumor progression 探索 miR-361-3p 在胃癌治疗和肿瘤进展中的作用
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.11.002
Kulsum Akhtar , Gowhar Rashid , Tahseen Bilal Rather , Irfan Maqbool , Ishrat Parveiz , Gulzar Ahmad Bhat , Fazl Q. Parray , Syed Besina Yasin , Syed Mudassar

Background

Gastric cancer (GC) remains a leading cause of cancer-related deaths globally. Even with advancements in treatment, it is not known precisely which molecular pathways cause GC to proceed. MicroRNAs, often referred to as small noncoding RNAs, have a crucial role in regulating gene expression, which impacts cancer growth, metastasis, and treatment resistance. Among these, miR-361–3p has drawn interest due to its possible role in the development of human cancer. While accumulating evidence highlights miR-361–3p involvement in various cancers, its precise biological function in gastric cancer remains largely unclear.

Methodology

The expression levels of miR-361–3p in gastric cancer tissues were compared with those of adjacent non-cancer tissues using real-time quantitative PCR (qRT-PCR). The investigation involved a thorough examination of the expression of miR-361–3p in GC samples in order to identify any possible correlations with clinicopathological characteristics.

Results

In 64.86 % of gastric cancer, expression levels of miR-361–3p mRNA were significantly reduced, which indicates that it may play a potential role in the pathophysiology of GC. However, no significant association has been found between miR-361–3p expression levels and clinical pathological features, such as tumor size, phase, or involvement of lymph nodes. This suggests that although miR-361–3p may contribute to GC progress, it is not related to traditional clinical markers.
背景胃癌(GC)仍然是全球癌症相关死亡的主要原因。即使在治疗方面取得了进展,但人们仍不清楚究竟是哪些分子途径导致了胃癌的发生。通常被称为小型非编码 RNA 的微 RNA 在调节基因表达方面起着至关重要的作用,而基因表达会影响癌症的生长、转移和耐药性。其中,miR-361-3p 因其在人类癌症发展中可能扮演的角色而备受关注。方法采用实时定量 PCR(qRT-PCR)技术比较了 miR-361-3p 在胃癌组织和邻近非癌组织中的表达水平。结果在 64.86% 的胃癌中,miR-361-3p mRNA 的表达水平显著降低,这表明它可能在胃癌的病理生理学中发挥潜在作用。然而,miR-361-3p 的表达水平与肿瘤大小、分期或淋巴结受累等临床病理特征之间没有发现明显的关联。这表明,虽然 miR-361-3p 可能有助于 GC 的进展,但它与传统的临床指标无关。
{"title":"Exploring the role of miR-361-3p in gastric cancer therapeutics and tumor progression","authors":"Kulsum Akhtar ,&nbsp;Gowhar Rashid ,&nbsp;Tahseen Bilal Rather ,&nbsp;Irfan Maqbool ,&nbsp;Ishrat Parveiz ,&nbsp;Gulzar Ahmad Bhat ,&nbsp;Fazl Q. Parray ,&nbsp;Syed Besina Yasin ,&nbsp;Syed Mudassar","doi":"10.1016/j.abst.2024.11.002","DOIUrl":"10.1016/j.abst.2024.11.002","url":null,"abstract":"<div><h3>Background</h3><div>Gastric cancer (GC) remains a leading cause of cancer-related deaths globally. Even with advancements in treatment, it is not known precisely which molecular pathways cause GC to proceed. MicroRNAs, often referred to as small noncoding RNAs, have a crucial role in regulating gene expression, which impacts cancer growth, metastasis, and treatment resistance. Among these, miR-361–3p has drawn interest due to its possible role in the development of human cancer. While accumulating evidence highlights miR-361–3p involvement in various cancers, its precise biological function in gastric cancer remains largely unclear.</div></div><div><h3>Methodology</h3><div>The expression levels of miR-361–3p in gastric cancer tissues were compared with those of adjacent non-cancer tissues using real-time quantitative PCR (qRT-PCR). The investigation involved a thorough examination of the expression of miR-361–3p in GC samples in order to identify any possible correlations with clinicopathological characteristics.</div></div><div><h3>Results</h3><div>In 64.86 % of gastric cancer, expression levels of miR-361–3p mRNA were significantly reduced, which indicates that it may play a potential role in the pathophysiology of GC. However, no significant association has been found between miR-361–3p expression levels and clinical pathological features, such as tumor size, phase, or involvement of lymph nodes. This suggests that although miR-361–3p may contribute to GC progress, it is not related to traditional clinical markers.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 260-264"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142652861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of urinary proteome in the first two days after mating in male rats 雄性大鼠交配后头两天尿液蛋白质组的比较
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.08.003
Haitong Wang, Chenyang Zhao, Youhe Gao

Objective

To explore whether differences between male rats on the next day of mating and on the day of mating can be reflected by the urine proteome.

Methods

Urine samples were collected from male Sprague-Dawley rats on the day of mating and the next day of mating. Urine samples were analysed by the label-free quantitative proteomics technique of high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS). Differential proteins of the urine proteome were analysed for protein function and biological pathways.

Results

54 differential proteins were identified by comparing the urine proteome of rats on the next day of mating with that on the day of mating, and nearly two-thirds of the differential proteins were related to spermatogenesis.

Conclusions

The urine proteome has the potential to reflect spermatogenesis without interfering with it.

目的 探讨雄性大鼠在交配次日和交配当日的差异是否能通过尿液蛋白质组反映出来。 方法 收集雄性 Sprague-Dawley 大鼠在交配当日和交配次日的尿液样本。采用高效液相色谱串联质谱(LC-MS/MS)无标记定量蛋白质组学技术对尿液样本进行分析。结果 通过比较大鼠交配次日与交配当日的尿液蛋白质组,发现了54种差异蛋白质,其中近三分之二的差异蛋白质与精子发生有关。
{"title":"Comparison of urinary proteome in the first two days after mating in male rats","authors":"Haitong Wang,&nbsp;Chenyang Zhao,&nbsp;Youhe Gao","doi":"10.1016/j.abst.2024.08.003","DOIUrl":"10.1016/j.abst.2024.08.003","url":null,"abstract":"<div><h3>Objective</h3><p>To explore whether differences between male rats on the next day of mating and on the day of mating can be reflected by the urine proteome.</p></div><div><h3>Methods</h3><p>Urine samples were collected from male Sprague-Dawley rats on the day of mating and the next day of mating. Urine samples were analysed by the label-free quantitative proteomics technique of high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS). Differential proteins of the urine proteome were analysed for protein function and biological pathways.</p></div><div><h3>Results</h3><p>54 differential proteins were identified by comparing the urine proteome of rats on the next day of mating with that on the day of mating, and nearly two-thirds of the differential proteins were related to spermatogenesis.</p></div><div><h3>Conclusions</h3><p>The urine proteome has the potential to reflect spermatogenesis without interfering with it.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 166-173"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000140/pdfft?md5=46d51b65f70f0cc0a9a8b2614e279c71&pid=1-s2.0-S2543106424000140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of vitamin B12 and vitamin D in T2DM patients in north Indian population 北印度人群中 T2DM 患者体内维生素 B12 和维生素 D 的关系
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.09.001
Ishdeep Singh, Vivek Kumar Garg

Introduction

Diabetes mellitus, highly prevalent endocrine disorder and metformin is the most frequently recommended oral hypoglycemic agent (OHA).

Methods

We recruited 100 individuals who were taking OHA including metformin more than one year as cases and 40 healthy individuals as control. The patients were divided into three groups. The first group, Group I (n = 58) patients taking metformin, group II (n = 42) patients taking OHA other than metformin and group III (n = 40), taken as control group.

Results

In groups I, II, and III, a considerable number of patients experienced low levels of vitamin B12 i.e. 42 (72.41 %), 8 (19.05 %), and 14 (35 %) respectively. When comparing all groups, p-value was highly significant (p = 0.000). 35 (60.36 %), 13(30.95 %), and 15(37.5 %) patients had insufficient levels of vitamin D in groups I, II, III respectively. On comparing, p-value was highly significant (p = 0.007).

Conclusion

The study concluded that long-term metformin treatment causes insufficiency and deficiency of vitamin D and vitamin B12, respectively.
方法 我们招募了 100 名服用包括二甲双胍在内的口服降糖药超过一年的患者作为病例,40 名健康人作为对照。患者分为三组。第一组为服用二甲双胍的患者(58 人),第二组为服用二甲双胍以外的 OHA 的患者(42 人),第三组为对照组(40 人)。结果 在第一组、第二组和第三组中,相当多的患者出现维生素 B12 含量低的情况,分别为 42 人(72.41%)、8 人(19.05%)和 14 人(35%)。比较所有组别,P 值非常显著(P = 0.000)。I 组、II 组和 III 组分别有 35(60.36 %)、13(30.95 %)和 15(37.5 %)名患者维生素 D 水平不足。结论该研究得出结论,长期二甲双胍治疗分别导致维生素 D 和维生素 B12 不足和缺乏。
{"title":"Association of vitamin B12 and vitamin D in T2DM patients in north Indian population","authors":"Ishdeep Singh,&nbsp;Vivek Kumar Garg","doi":"10.1016/j.abst.2024.09.001","DOIUrl":"10.1016/j.abst.2024.09.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Diabetes mellitus, highly prevalent endocrine disorder and metformin is the most frequently recommended oral hypoglycemic agent (OHA).</div></div><div><h3>Methods</h3><div>We recruited 100 individuals who were taking OHA including metformin more than one year as cases and 40 healthy individuals as control. The patients were divided into three groups. The first group, Group I (n = 58) patients taking metformin, group II (n = 42) patients taking OHA other than metformin and group III (n = 40), taken as control group.</div></div><div><h3>Results</h3><div>In groups I, II, and III, a considerable number of patients experienced low levels of vitamin B12 i.e. 42 (72.41 %), 8 (19.05 %), and 14 (35 %) respectively. When comparing all groups, p-value was highly significant (p = 0.000). 35 (60.36 %), 13(30.95 %), and 15(37.5 %) patients had insufficient levels of vitamin D in groups I, II, III respectively. On comparing, p-value was highly significant (p = 0.007).</div></div><div><h3>Conclusion</h3><div>The study concluded that long-term metformin treatment causes insufficiency and deficiency of vitamin D and vitamin B12, respectively.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 209-216"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene-environment interactions and colorectal cancer risk: A case-control study on xenobiotic metabolizing enzyme polymorphisms in the Jammu& Kashmir, India population 基因-环境相互作用与结直肠癌风险:印度查谟和克什米尔人群中异生物代谢酶多态性的病例对照研究
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.10.001
Gowhar Rashid , Gulzar A. Bhat , Tahseen Bilal Rather , Kulsum Akhter , Ishrat Parveiz , Irfan Maqbool , Syed Nisar Ahmad , Malik Tariq Rasool , Farooq Ahmad Jan , Syed Mudassar

Background

Cancer remains a significant global health concern, with colorectal cancer (CRC) showing a rising incidence, particularly among younger populations. Most CRC cases are linked to a complex interplay of genetic and environmental factors. The cytochrome P450 (CYP) superfamily, including enzymes like CYP2A13 and CYP2A6, plays a vital role in metabolizing environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) and nitrosamines. Polymorphisms in these genes, alongside phase II glutathione-S-transferases (GSTs) involved in detoxification, can influence individual cancer risk. This study focuses on the association between these genetic polymorphisms and CRC risk in the Jammu & Kashmir, population, a region with high exposure to dietary and lifestyle-related carcinogens.

Methodology

This hospital-based case-control study was conducted at the Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, India between March 2019 and March 2022. The study included 246 histopathologically confirmed colorectal cancer (CRC) cases, and an equal number of matched controls based on age (±5 years), gender, and place of residence. Blood samples were collected for DNA extraction, followed by genotyping of xenobiotic-metabolizing enzyme (XME) genes, including CYP2A13, CYP2A6, and GSTs using standard PCR-RFLP and multiplex PCR methods. Statistical analyses were performed using STATA software to assess the association between gene polymorphisms and CRC risk.

Results

The study revealed key associations between genetic and environmental factors and CRC risk. The analysis demonstrated that cases had significantly lower education levels than controls. Family history of cancer, smoking, and dietary factors like red meat and salt tea consumption were more prevalent among cases. Genetic analysis identified significant interactions between various CYP and GST genotypes, and environmental factors such as smoking, pesticide exposure, and diet, with varying effects on CRC risk.

Conclusion

The research underscores the influence of genetic and environmental factors on colorectal cancer (CRC) risk. Lower educational was associated with a heightened risk of CRC. Certain genotype variants of xenobiotic metabolizing enzymes (XME) were found to increase CRC risk, particularly in conjunction with smoking, pesticide exposure, and sun-dried vegetable consumption. A family history of cancer, especially CRC, further amplified the risk. These findings emphasize the importance of developing personalized CRC prevention and screening strategies that account for gene-environment interactions.
背景癌症仍然是全球关注的重大健康问题,结直肠癌(CRC)的发病率呈上升趋势,尤其是在年轻人群中。大多数 CRC 病例与复杂的遗传和环境因素相互作用有关。细胞色素 P450(CYP)超家族,包括 CYP2A13 和 CYP2A6 等酶,在代谢多环芳烃(PAHs)和亚硝胺等环境致癌物方面发挥着重要作用。这些基因的多态性以及参与解毒的第二阶段谷胱甘肽-S-转移酶(GSTs)可影响个人患癌风险。本研究的重点是查谟&克什米尔人群中这些基因多态性与 CRC 风险之间的关联,该地区的饮食和生活方式相关致癌物质暴露量较高。方法这项基于医院的病例对照研究于 2019 年 3 月至 2022 年 3 月在印度 J&K 的斯利那加 Sher-I-Kashmir 医学科学研究所 (SKIMS) 进行。研究包括 246 例经组织病理学确诊的结直肠癌(CRC)病例,以及同等数量的基于年龄(±5 岁)、性别和居住地的匹配对照。采集血样进行 DNA 提取,然后使用标准 PCR-RFLP 和多重 PCR 方法对包括 CYP2A13、CYP2A6 和 GSTs 在内的异生物代谢酶(XME)基因进行基因分型。使用 STATA 软件进行统计分析,评估基因多态性与 CRC 风险之间的关联。分析表明,病例的受教育程度明显低于对照组。癌症家族史、吸烟以及红肉和盐茶等饮食因素在病例中更为普遍。遗传分析发现,各种 CYP 和 GST 基因型与吸烟、接触杀虫剂和饮食等环境因素之间存在明显的相互作用,对 CRC 风险的影响各不相同。教育程度较低与罹患 CRC 的风险增加有关。研究发现,异生物代谢酶(XME)的某些基因型变异会增加患 CRC 的风险,尤其是与吸烟、接触杀虫剂和食用晒干的蔬菜有关。有癌症家族史,尤其是有 CRC 家族史,会进一步增加患病风险。这些发现强调了制定考虑基因与环境相互作用的个性化 CRC 预防和筛查策略的重要性。
{"title":"Gene-environment interactions and colorectal cancer risk: A case-control study on xenobiotic metabolizing enzyme polymorphisms in the Jammu& Kashmir, India population","authors":"Gowhar Rashid ,&nbsp;Gulzar A. Bhat ,&nbsp;Tahseen Bilal Rather ,&nbsp;Kulsum Akhter ,&nbsp;Ishrat Parveiz ,&nbsp;Irfan Maqbool ,&nbsp;Syed Nisar Ahmad ,&nbsp;Malik Tariq Rasool ,&nbsp;Farooq Ahmad Jan ,&nbsp;Syed Mudassar","doi":"10.1016/j.abst.2024.10.001","DOIUrl":"10.1016/j.abst.2024.10.001","url":null,"abstract":"<div><h3>Background</h3><div>Cancer remains a significant global health concern, with colorectal cancer (CRC) showing a rising incidence, particularly among younger populations. Most CRC cases are linked to a complex interplay of genetic and environmental factors. The cytochrome P450 (CYP) superfamily, including enzymes like CYP2A13 and CYP2A6, plays a vital role in metabolizing environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) and nitrosamines. Polymorphisms in these genes, alongside phase II glutathione-S-transferases (GSTs) involved in detoxification, can influence individual cancer risk. This study focuses on the association between these genetic polymorphisms and CRC risk in the Jammu &amp; Kashmir, population, a region with high exposure to dietary and lifestyle-related carcinogens.</div></div><div><h3>Methodology</h3><div>This hospital-based case-control study was conducted at the Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&amp;K, India between March 2019 and March 2022. The study included 246 histopathologically confirmed colorectal cancer (CRC) cases, and an equal number of matched controls based on age (±5 years), gender, and place of residence. Blood samples were collected for DNA extraction, followed by genotyping of xenobiotic-metabolizing enzyme (XME) genes, including CYP2A13, CYP2A6, and GSTs using standard PCR-RFLP and multiplex PCR methods. Statistical analyses were performed using STATA software to assess the association between gene polymorphisms and CRC risk.</div></div><div><h3>Results</h3><div>The study revealed key associations between genetic and environmental factors and CRC risk. The analysis demonstrated that cases had significantly lower education levels than controls. Family history of cancer, smoking, and dietary factors like red meat and salt tea consumption were more prevalent among cases. Genetic analysis identified significant interactions between various CYP and GST genotypes, and environmental factors such as smoking, pesticide exposure, and diet, with varying effects on CRC risk.</div></div><div><h3>Conclusion</h3><div>The research underscores the influence of genetic and environmental factors on colorectal cancer (CRC) risk. Lower educational was associated with a heightened risk of CRC. Certain genotype variants of xenobiotic metabolizing enzymes (XME) were found to increase CRC risk, particularly in conjunction with smoking, pesticide exposure, and sun-dried vegetable consumption. A family history of cancer, especially CRC, further amplified the risk. These findings emphasize the importance of developing personalized CRC prevention and screening strategies that account for gene-environment interactions.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 227-241"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paper based molecularly imprinted SERS substrate for early detection of lysophosphatidic acid in ovarian cancer 用于早期检测卵巢癌溶血磷脂酸的纸基分子印迹 SERS 底物
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.03.001
Nazia Tarannum , Deepak Kumar , Akanksha Yadav , Anil K. Yadav

The current study is related to fabrication of point-of-care molecularly imprinted paper-based analytical devices, specifically related to ovarian cancer early stage detection. The task involves creating a paper coated with silver nanoparticles (AgNPs) that can be used as a transducer via surface enhanced Raman spectroscopy (SERS) to detect the threshold level of the biomarker lysophosphatidic acid (LPA) as a template molecule to diagnose ovarian cancer. MIPs are synthetic receptors designed for a targeted molecule which are prepared from polymers in the presence of target such as small molecules, proteins or cells etc. Removal of the template results in cavities which are structurally and electrostatically complementary to the template molecule. The molecularly imprinted polymer (MIP) layer was anchored on vinyl trimethoxy silane modified-paper, which served as a detector by hydrolytically modifying the paper surface with vinyl trimethoxy silane. To detect LPA in serum samples for ovarian cancer, MIP-paper based on SERS was developed. Patients with benign ovarian tumors had an LPA level of 7.73 μM whereas those with ovarian cancer have a level of 16.99 μM. A healthy person's LPA level is 2.92 μM. Consequently, the rise in LPA levels may aid in the early detection of ovarian cancer. The study refers to the use of a point of care device to diagnose ovarian cancer early, which should be simple, effective, and cost-effective. The analytical tool in the study is a sensor with high selectivity and sensitivity, quick assay times, and inexpensive costs. For LPA in serum, the binding constant of modified paper-based MIP ranges from 11.00 μM to 0.08 μM. The amalgamation of nanoparticles on 2D-paper with MIP have lead to develop sensor which can effectively select LPA in untreated real samples like serum.

目前的研究涉及制造基于分子印迹纸的护理点分析设备,特别是与卵巢癌早期检测有关的设备。这项任务涉及制作一种涂有银纳米粒子(AgNPs)的纸,通过表面增强拉曼光谱(SERS)将其用作传感器,以检测作为模板分子的生物标志物溶血磷脂酸(LPA)的阈值水平,从而诊断卵巢癌。MIPs 是为目标分子设计的合成受体,由聚合物在目标分子(如小分子、蛋白质或细胞等)存在的情况下制备而成。去除模板后,就会形成在结构上和静电上与模板分子互补的空腔。分子印迹聚合物(MIP)层锚定在乙烯基三甲氧基硅烷改性纸上,通过乙烯基三甲氧基硅烷对纸表面进行水解改性,使其成为检测器。为了检测卵巢癌血清样本中的 LPA,开发了基于 SERS 的 MIP 纸。良性卵巢肿瘤患者的 LPA 含量为 7.73 μM,而卵巢癌患者的 LPA 含量为 16.99 μM。健康人的 LPA 水平为 2.92 μM。因此,LPA 水平的升高可能有助于早期发现卵巢癌。这项研究是指使用一种护理点设备来早期诊断卵巢癌,它应该是简单、有效和具有成本效益的。研究中的分析工具是一种具有高选择性和高灵敏度、快速检测时间和低成本的传感器。对于血清中的 LPA,改性纸基 MIP 的结合常数从 11.00 μM 到 0.08 μM。将二维纸上的纳米粒子与 MIP 相结合,开发出了一种传感器,可以在未经处理的真实样品(如血清)中有效地选择 LPA。
{"title":"Paper based molecularly imprinted SERS substrate for early detection of lysophosphatidic acid in ovarian cancer","authors":"Nazia Tarannum ,&nbsp;Deepak Kumar ,&nbsp;Akanksha Yadav ,&nbsp;Anil K. Yadav","doi":"10.1016/j.abst.2024.03.001","DOIUrl":"https://doi.org/10.1016/j.abst.2024.03.001","url":null,"abstract":"<div><p>The current study is related to fabrication of point-of-care molecularly imprinted paper-based analytical devices, specifically related to ovarian cancer early stage detection. The task involves creating a paper coated with silver nanoparticles (AgNPs) that can be used as a transducer via surface enhanced Raman spectroscopy (SERS) to detect the threshold level of the biomarker lysophosphatidic acid (LPA) as a template molecule to diagnose ovarian cancer. MIPs are synthetic receptors designed for a targeted molecule which are prepared from polymers in the presence of target such as small molecules, proteins or cells etc. Removal of the template results in cavities which are structurally and electrostatically complementary to the template molecule. The molecularly imprinted polymer (MIP) layer was anchored on vinyl trimethoxy silane modified-paper, which served as a detector by hydrolytically modifying the paper surface with vinyl trimethoxy silane. To detect LPA in serum samples for ovarian cancer, MIP-paper based on SERS was developed. Patients with benign ovarian tumors had an LPA level of 7.73 μM whereas those with ovarian cancer have a level of 16.99 μM. A healthy person's LPA level is 2.92 μM. Consequently, the rise in LPA levels may aid in the early detection of ovarian cancer. The study refers to the use of a point of care device to diagnose ovarian cancer early, which should be simple, effective, and cost-effective. The analytical tool in the study is a sensor with high selectivity and sensitivity, quick assay times, and inexpensive costs. For LPA in serum, the binding constant of modified paper-based MIP ranges from 11.00 μM to 0.08 μM. The amalgamation of nanoparticles on 2D-paper with MIP have lead to develop sensor which can effectively select LPA in untreated real samples like serum.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 46-58"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S254310642400005X/pdfft?md5=7c83ba4ed035c0849ec0fbb408562405&pid=1-s2.0-S254310642400005X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140339801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Faecal microbial transplant 粪便微生物移植
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.02.001
Isreal Ayobami Onifade , Oluwatomiwa Jubilee Sunbare-Funto , Chinedu Endurance Mbah , Oluwatosin Akinola Ajibade , Olubukola Monisola Oyawoye , Abdullahi Tunde Aborode , Seto Charles Ogunleye , Abdullahi Jamiu , Basit Bolarinwa , Mosope F. Abanikannda , Zainab Tiamiyu , Abidemi Ruth Idowu , Oluwatobiloba Ige , Opara Julia Kelechi , Jeremiah I. Abok , Eniola A. Lawal , Ibude Jane Aruorivwooghene , Adekunle Fatai Adeoye , Olowo Roqeebah , Emmanuel Akinloye Ojewole , Ridwan Olamilekan Adesola

Faecal Microbial Transplantation (FMT), have been shown to be successfully managed along with a variety of gastrointestinal disorders, including Clostridioides difficile infection (CDI), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). FMT is a medical procedure that involves a donor transferring healthy gut bacteria to the recipient. The effectiveness of FMT is thought to be due to the ability of the healthy gut to restore balance to the recipient's microbiome, which is the community of microorganisms that inhabit the gastrointestinal tract. One of the key advantages of FMT is that it is a relatively simple and low-cost treatment option, compared to other therapies that may be more invasive or require long-term medication use. However, FMT is not without its limitations, including the potential for the transfer of infectious agents from the donor to the recipient and the potential for negative side effects in some patients. In this research, we discuss the current state of the evidence on FMT, including its potential benefits and risks, as well as future directions for research in this area.

粪便微生物移植(FMT)已被证明可以成功控制各种胃肠道疾病,包括艰难梭菌感染(CDI)、炎症性肠病(IBD)和肠易激综合征(IBS)。FMT 是一种医疗程序,由供体将健康的肠道细菌转移给受体。FMT 的有效性被认为是由于健康肠道能够恢复受体微生物组的平衡,而微生物组是居住在胃肠道中的微生物群落。FMT 的主要优势之一是,与其他可能更具侵入性或需要长期用药的疗法相比,它是一种相对简单且成本较低的治疗方案。然而,FMT 也并非没有局限性,包括可能将传染性病原体从供体转移到受体,以及可能对某些患者产生负面影响。在本研究中,我们将讨论 FMT 目前的证据状况,包括其潜在的益处和风险,以及该领域未来的研究方向。
{"title":"Faecal microbial transplant","authors":"Isreal Ayobami Onifade ,&nbsp;Oluwatomiwa Jubilee Sunbare-Funto ,&nbsp;Chinedu Endurance Mbah ,&nbsp;Oluwatosin Akinola Ajibade ,&nbsp;Olubukola Monisola Oyawoye ,&nbsp;Abdullahi Tunde Aborode ,&nbsp;Seto Charles Ogunleye ,&nbsp;Abdullahi Jamiu ,&nbsp;Basit Bolarinwa ,&nbsp;Mosope F. Abanikannda ,&nbsp;Zainab Tiamiyu ,&nbsp;Abidemi Ruth Idowu ,&nbsp;Oluwatobiloba Ige ,&nbsp;Opara Julia Kelechi ,&nbsp;Jeremiah I. Abok ,&nbsp;Eniola A. Lawal ,&nbsp;Ibude Jane Aruorivwooghene ,&nbsp;Adekunle Fatai Adeoye ,&nbsp;Olowo Roqeebah ,&nbsp;Emmanuel Akinloye Ojewole ,&nbsp;Ridwan Olamilekan Adesola","doi":"10.1016/j.abst.2024.02.001","DOIUrl":"10.1016/j.abst.2024.02.001","url":null,"abstract":"<div><p>Faecal Microbial Transplantation (FMT), have been shown to be successfully managed along with a variety of gastrointestinal disorders, including <em>Clostridioides difficile</em> infection (CDI), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). FMT is a medical procedure that involves a donor transferring healthy gut bacteria to the recipient. The effectiveness of FMT is thought to be due to the ability of the healthy gut to restore balance to the recipient's microbiome, which is the community of microorganisms that inhabit the gastrointestinal tract. One of the key advantages of FMT is that it is a relatively simple and low-cost treatment option, compared to other therapies that may be more invasive or require long-term medication use. However, FMT is not without its limitations, including the potential for the transfer of infectious agents from the donor to the recipient and the potential for negative side effects in some patients. In this research, we discuss the current state of the evidence on FMT, including its potential benefits and risks, as well as future directions for research in this area.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 20-34"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000036/pdfft?md5=2c2f7c6deba6132e414ddec7623c4461&pid=1-s2.0-S2543106424000036-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139877860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of cognitive computing in enhancing innovative healthcare solutions 认知计算在加强创新医疗解决方案中的作用
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.08.002
Abid Haleem, Mohd Javaid

Cognitive computing represents a groundbreaking development in healthcare, encompassing technological platforms that emulate the human brain's functionality. While cloud computing offers on-demand internet access to computing resources and services, cognitive computing focuses on modelling human mental processes to tackle complicated issues. Cognitive computing enhances human decision-making by integrating reasoning, machine learning, speech, natural language processing (NLP), and human-computer interaction. In the healthcare sector, it facilitates the analysis of clinical and genetic data to forecast diseases, tailor therapies, and elevate drug development. Additionally, it combines data analysis with adaptive page displays to tailor content based on the audience. Relevant papers in cognitive computing for healthcare were identified and studied. This paper aims to undertake an extensive scopic review of the pertinent literature from various sources, including articles and documents from numerous journals and conference proceedings. It delves into the need for cognitive computing in healthcare, elucidates supportive technologies, and expounds on its features within the healthcare domain. Furthermore, it identifies and discusses the substantial applications of cognitive computing in healthcare. These systems utilise computer models to replicate human cognitive processes, streamlining administrative tasks through artificial intelligence and cognitive computing. As a result, healthcare administrators can allocate more of their valuable time to patient care. Cognitive computing enhances outcomes and practitioner productivity and improves treatment decisions. The self-learning system of cognitive computing relies on real-time patient data, medical transcripts, and other pertinent information. These technologies can reduce the administrative burden on healthcare workers by automating tasks such as invoicing, claims processing, and appointment scheduling. This technology is poised to become increasingly indispensable in precision medicine.

认知计算代表着医疗保健领域的突破性发展,它包括模拟人脑功能的技术平台。云计算提供按需访问互联网的计算资源和服务,而认知计算则侧重于模拟人类的心理过程,以解决复杂的问题。认知计算通过整合推理、机器学习、语音、自然语言处理(NLP)和人机交互来增强人类的决策能力。在医疗保健领域,认知计算有助于分析临床和基因数据,以预测疾病、定制治疗方案并促进药物开发。此外,它还能将数据分析与自适应页面显示相结合,根据受众情况定制内容。本文确定并研究了认知计算在医疗保健领域的相关论文。本文旨在对各种来源的相关文献(包括众多期刊和会议论文集中的文章和文件)进行广泛的综述。它深入探讨了医疗保健领域对认知计算的需求,阐明了支持性技术,并阐述了其在医疗保健领域的特点。此外,它还确定并讨论了认知计算在医疗保健领域的大量应用。这些系统利用计算机模型复制人类的认知过程,通过人工智能和认知计算简化管理任务。因此,医疗保健管理人员可以将更多宝贵时间分配给病人护理工作。认知计算可提高疗效和从业人员的工作效率,并改进治疗决策。认知计算的自学习系统依赖于实时患者数据、医疗记录和其他相关信息。这些技术可以自动执行发票开具、索赔处理和预约安排等任务,从而减轻医护人员的行政负担。在精准医疗领域,这项技术将变得越来越不可或缺。
{"title":"Role of cognitive computing in enhancing innovative healthcare solutions","authors":"Abid Haleem,&nbsp;Mohd Javaid","doi":"10.1016/j.abst.2024.08.002","DOIUrl":"10.1016/j.abst.2024.08.002","url":null,"abstract":"<div><p>Cognitive computing represents a groundbreaking development in healthcare, encompassing technological platforms that emulate the human brain's functionality. While cloud computing offers on-demand internet access to computing resources and services, cognitive computing focuses on modelling human mental processes to tackle complicated issues. Cognitive computing enhances human decision-making by integrating reasoning, machine learning, speech, natural language processing (NLP), and human-computer interaction. In the healthcare sector, it facilitates the analysis of clinical and genetic data to forecast diseases, tailor therapies, and elevate drug development. Additionally, it combines data analysis with adaptive page displays to tailor content based on the audience. Relevant papers in cognitive computing for healthcare were identified and studied. This paper aims to undertake an extensive scopic review of the pertinent literature from various sources, including articles and documents from numerous journals and conference proceedings. It delves into the need for cognitive computing in healthcare, elucidates supportive technologies, and expounds on its features within the healthcare domain. Furthermore, it identifies and discusses the substantial applications of cognitive computing in healthcare. These systems utilise computer models to replicate human cognitive processes, streamlining administrative tasks through artificial intelligence and cognitive computing. As a result, healthcare administrators can allocate more of their valuable time to patient care. Cognitive computing enhances outcomes and practitioner productivity and improves treatment decisions. The self-learning system of cognitive computing relies on real-time patient data, medical transcripts, and other pertinent information. These technologies can reduce the administrative burden on healthcare workers by automating tasks such as invoicing, claims processing, and appointment scheduling. This technology is poised to become increasingly indispensable in precision medicine.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 152-165"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000139/pdfft?md5=cb7d5fbc41d9253461511cb165aed156&pid=1-s2.0-S2543106424000139-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142088999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-derived primary culture-based prognostic model to predict tumor recurrence in patients with glioma 预测胶质瘤患者肿瘤复发的基于患者原代培养的预后模型
Pub Date : 2024-01-01 DOI: 10.1016/j.abst.2024.01.002
Syed Sultan Beevi , Manas Kumar Panigrahi , Vinod Kumar Verma , Jyotsana Dwivedi , Sailaja Madigubba , Radhika Chowdary Darapuneni , Seema M. Gafurjiwala , Sambit Sahu , Bhaskar Rao Bollineni

Background

The prognosis for glioma patients remains grim despite aggressive treatment approaches. Current molecular profiles have limitations in predicting glioma recurrence, highlighting the need for new and improved prognostic biomarkers. We investigated whether the growth kinetics of patient-derived glioma cultures (PDGCs) can offer valuable prognostic insights to predict tumor recurrence. Additionally, we examined the expression of glial-mesenchymal transition (GMT) markers in PDGCs to assess their potential as additional prognostic biomarkers.

Methods

130 patients diagnosed with primary glioma via MRI scans were prospectively enrolled. Surgical tumor tissues were collected from all participants and used to establish patient-derived glioma cultures (PDGCs). The growth kinetics and colony-forming ability of the respective PDGCs were calculated to derive proliferation index (PI) for each patient. Progression-free survival (PFS) and overall survival (OS) served as the primary outcome measures.

Results

We established short-term glioma cultures in 98 clinical samples, regardless of the CNS WHO tumor grade, IDH1/2 mutation and 19/19q codeletion status and maintained active cell proliferation for at least 10–12 passages. However, we observed two distinct growth kinetic patterns among PDGCs. Based on their proliferation index (PI), we categorized patients into either high proliferation index (HPI) or low proliferation index (LPI) group. Furthermore, we noted a differential expression profile of GMT markers between HPI and LPI patients. The proliferation index (PI) exhibited a significant correlation with progression-free survival (PFS), while the expression of GMT marker vimentin was associated with overall survival (OS).

Conclusion

The PDGC-derived Proliferation Index (PI) can serve as a predictive tool for tumor recurrence, independent of clinical or tumor-related factors. Moreover, reduced vimentin expression is a positive indicator for glioma patients' overall survival status.

背景尽管采取了积极的治疗方法,但胶质瘤患者的预后仍然不容乐观。目前的分子图谱在预测胶质瘤复发方面存在局限性,这凸显了对新的、更好的预后生物标志物的需求。我们研究了患者衍生胶质瘤培养物(PDGCs)的生长动力学能否为预测肿瘤复发提供有价值的预后见解。此外,我们还研究了胶质-间质转化(GMT)标记物在 PDGCs 中的表达,以评估它们作为额外预后生物标记物的潜力。收集了所有参与者的手术肿瘤组织,并用于建立患者衍生胶质瘤培养物(PDGCs)。通过计算各PDGCs的生长动力学和集落形成能力,得出每位患者的增殖指数(PI)。结果我们在98份临床样本中建立了短期胶质瘤培养物,无论中枢神经系统WHO肿瘤分级、IDH1/2突变和19/19q编码缺失状态如何,这些培养物都能保持活跃的细胞增殖至少10-12次。然而,我们观察到 PDGCs 有两种不同的生长动力学模式。根据增殖指数(PI),我们将患者分为高增殖指数组(HPI)和低增殖指数组(LPI)。此外,我们还注意到高增殖指数组和低增殖指数组患者的 GMT 标志物表达谱存在差异。增殖指数(PI)与无进展生存期(PFS)呈显著相关性,而 GMT 标志物波形蛋白的表达与总生存期(OS)相关。此外,波形蛋白表达的减少是胶质瘤患者总生存状况的一个积极指标。
{"title":"Patient-derived primary culture-based prognostic model to predict tumor recurrence in patients with glioma","authors":"Syed Sultan Beevi ,&nbsp;Manas Kumar Panigrahi ,&nbsp;Vinod Kumar Verma ,&nbsp;Jyotsana Dwivedi ,&nbsp;Sailaja Madigubba ,&nbsp;Radhika Chowdary Darapuneni ,&nbsp;Seema M. Gafurjiwala ,&nbsp;Sambit Sahu ,&nbsp;Bhaskar Rao Bollineni","doi":"10.1016/j.abst.2024.01.002","DOIUrl":"https://doi.org/10.1016/j.abst.2024.01.002","url":null,"abstract":"<div><h3>Background</h3><p>The prognosis for glioma patients remains grim despite aggressive treatment approaches. Current molecular profiles have limitations in predicting glioma recurrence, highlighting the need for new and improved prognostic biomarkers. We investigated whether the growth kinetics of patient-derived glioma cultures (PDGCs) can offer valuable prognostic insights to predict tumor recurrence. Additionally, we examined the expression of glial-mesenchymal transition (GMT) markers in PDGCs to assess their potential as additional prognostic biomarkers.</p></div><div><h3>Methods</h3><p>130 patients diagnosed with primary glioma via MRI scans were prospectively enrolled. Surgical tumor tissues were collected from all participants and used to establish patient-derived glioma cultures (PDGCs). The growth kinetics and colony-forming ability of the respective PDGCs were calculated to derive proliferation index (PI) for each patient. Progression-free survival (PFS) and overall survival (OS) served as the primary outcome measures.</p></div><div><h3>Results</h3><p>We established short-term glioma cultures in 98 clinical samples, regardless of the CNS WHO tumor grade, IDH1/2 mutation and 19/19q codeletion status and maintained active cell proliferation for at least 10–12 passages. However, we observed two distinct growth kinetic patterns among PDGCs. Based on their proliferation index (PI), we categorized patients into either high proliferation index (HPI) or low proliferation index (LPI) group. Furthermore, we noted a differential expression profile of GMT markers between HPI and LPI patients. The proliferation index (PI) exhibited a significant correlation with progression-free survival (PFS), while the expression of GMT marker vimentin was associated with overall survival (OS).</p></div><div><h3>Conclusion</h3><p>The PDGC-derived Proliferation Index (PI) can serve as a predictive tool for tumor recurrence, independent of clinical or tumor-related factors. Moreover, reduced vimentin expression is a positive indicator for glioma patients' overall survival status.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 8-19"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000024/pdfft?md5=96223fcb0f1a5608cce72f2403943389&pid=1-s2.0-S2543106424000024-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139700168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in biomarker sciences and technology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1